p53 and response to chemotherapy and radiotherapy.
Ruley
H E
HE
Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000235:genetics; D002455:Cell Division / Q000235:genetics; D002471:Cell Transformation, Neoplastic / Q000235:genetics; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000187:drug effects / Q000528:radiation effects; D018450:Disease Progression; D018432:Drug Resistance, Multiple / Q000235:genetics; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D017353:Gene Deletion; D005786:Gene Expression Regulation; D016158:Genes, p53; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy; D009857:Oncogenes; D011379:Prognosis; D011878:Radiotherapy; D016159:Tumor Suppressor Protein p53 / Q000502:physiology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D016159:Tumor Suppressor Protein p53